Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249143558> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4249143558 endingPage "1" @default.
- W4249143558 startingPage "1" @default.
- W4249143558 abstract "Purpose: To examine the efficacy of second-generation-antipsychotics (SGAs) in the treatment of negative symptoms in Schizophrenia. Methods: Two meta-analyses were carried out using placebo or haloperidol as comparators. Studies were identified by searching for randomized, double-blind, placebo and/or haloperidol -controlled trials reporting data on efficacy of SGAs. Search was extended to the following databases: Pubmed, the Cochrane Central Register of Controlled Trials, Proquest Health and Medical Complete, Science Citation Index Expanded, and Current Contents Connect. the outcome measure used was the change in negative symptoms, choosing a standardized statistic (Cohen's d) to synthesize data. Results: A total of 46 homogeneous trials (Q=45.18, df=50, p=0.667, I 2 =0%) were included. in the placebo-controlled meta-analysis, the effect sizes (Cohen's d) obtained for amisulpride, haloperidol, olanzapine, quetiapine, risperidone and ziprasidone were 0.52, 0.34, 0.43, 0.36, 0.40 and 0.46, respectively, favoring active treatment against placebo (p< 0.001 in all cases). Comparing SGAs against haloperidol, showed just a statistically significant trend favoring SGA's in treatment of negative symptoms (Cohen's d = 0.15, p=0.008). Comparisons by drug showed a significant low and low-to-moderate standardized mean favoring SGA: Cohen's d = 0.34, p< 0.001; Cohen's d = 0.27, p< 0.001 and Cohen's d = 0.19, p=0.030, respectively for ziprasidone, risperidone and olanzapine. Conclusion: Most antipsychotics (aminosulpride, haloperidol, olanzapine. quetiapine, risperidone, ziprasidone) are effective in treatment of negative symptoms, showing moderate effect sizes. Amisulpride and ziprasidone were slightly better than the rest of drugs when compared with placebo. Compared with haloperidol, SGA showed controversial results." @default.
- W4249143558 created "2022-05-12" @default.
- W4249143558 creator A5032608456 @default.
- W4249143558 creator A5037317953 @default.
- W4249143558 creator A5048659786 @default.
- W4249143558 creator A5071705689 @default.
- W4249143558 creator A5084549749 @default.
- W4249143558 date "2009-01-01" @default.
- W4249143558 modified "2023-09-29" @default.
- W4249143558 title "Antipsychotics Efficacy in Treatment of Schizophrenia Negative Symptoms: Meta-analysis of Randomized Clinical Trials" @default.
- W4249143558 doi "https://doi.org/10.1016/s0924-9338(09)71420-8" @default.
- W4249143558 hasPublicationYear "2009" @default.
- W4249143558 type Work @default.
- W4249143558 citedByCount "0" @default.
- W4249143558 crossrefType "journal-article" @default.
- W4249143558 hasAuthorship W4249143558A5032608456 @default.
- W4249143558 hasAuthorship W4249143558A5037317953 @default.
- W4249143558 hasAuthorship W4249143558A5048659786 @default.
- W4249143558 hasAuthorship W4249143558A5071705689 @default.
- W4249143558 hasAuthorship W4249143558A5084549749 @default.
- W4249143558 hasBestOaLocation W42491435581 @default.
- W4249143558 hasConcept C118552586 @default.
- W4249143558 hasConcept C126322002 @default.
- W4249143558 hasConcept C142724271 @default.
- W4249143558 hasConcept C15744967 @default.
- W4249143558 hasConcept C168563851 @default.
- W4249143558 hasConcept C204787440 @default.
- W4249143558 hasConcept C27081682 @default.
- W4249143558 hasConcept C2776412080 @default.
- W4249143558 hasConcept C2776619155 @default.
- W4249143558 hasConcept C2777270317 @default.
- W4249143558 hasConcept C2778999636 @default.
- W4249143558 hasConcept C2780057945 @default.
- W4249143558 hasConcept C2780634440 @default.
- W4249143558 hasConcept C2780948584 @default.
- W4249143558 hasConcept C513476851 @default.
- W4249143558 hasConcept C71924100 @default.
- W4249143558 hasConceptScore W4249143558C118552586 @default.
- W4249143558 hasConceptScore W4249143558C126322002 @default.
- W4249143558 hasConceptScore W4249143558C142724271 @default.
- W4249143558 hasConceptScore W4249143558C15744967 @default.
- W4249143558 hasConceptScore W4249143558C168563851 @default.
- W4249143558 hasConceptScore W4249143558C204787440 @default.
- W4249143558 hasConceptScore W4249143558C27081682 @default.
- W4249143558 hasConceptScore W4249143558C2776412080 @default.
- W4249143558 hasConceptScore W4249143558C2776619155 @default.
- W4249143558 hasConceptScore W4249143558C2777270317 @default.
- W4249143558 hasConceptScore W4249143558C2778999636 @default.
- W4249143558 hasConceptScore W4249143558C2780057945 @default.
- W4249143558 hasConceptScore W4249143558C2780634440 @default.
- W4249143558 hasConceptScore W4249143558C2780948584 @default.
- W4249143558 hasConceptScore W4249143558C513476851 @default.
- W4249143558 hasConceptScore W4249143558C71924100 @default.
- W4249143558 hasIssue "S1" @default.
- W4249143558 hasLocation W42491435581 @default.
- W4249143558 hasOpenAccess W4249143558 @default.
- W4249143558 hasPrimaryLocation W42491435581 @default.
- W4249143558 hasRelatedWork W1546467468 @default.
- W4249143558 hasRelatedWork W1948712038 @default.
- W4249143558 hasRelatedWork W1951236991 @default.
- W4249143558 hasRelatedWork W1985202323 @default.
- W4249143558 hasRelatedWork W1985570731 @default.
- W4249143558 hasRelatedWork W2058525467 @default.
- W4249143558 hasRelatedWork W2078481675 @default.
- W4249143558 hasRelatedWork W2767514304 @default.
- W4249143558 hasRelatedWork W3102273891 @default.
- W4249143558 hasRelatedWork W1978844515 @default.
- W4249143558 hasVolume "24" @default.
- W4249143558 isParatext "false" @default.
- W4249143558 isRetracted "false" @default.
- W4249143558 workType "article" @default.